Strategic partnerships Leverage VintaBio’s collaboration model with biotech sponsors, contract development and manufacturing organizations (CDMOs), and leading research institutions to expand reach in viral vector manufacturing for AAV, LVV, and other platforms.

scalable production Target mid to late-stage gene therapy programs seeking reliable clinical supply with predictable timelines and reduced impurity burden, highlighting VintaBio’s scalable adherent manufacturing and process control.

Geographic hub Position Philadelphia Navy Yard as a value proposition for cost-efficient, proximity-based manufacturing to American gene therapy clients, emphasizing access to a thriving cell and gene therapy ecosystem.

Innovation credentials Capitalize on VintaBio’s data from VintaProcess and ongoing ASGCT presentations to support conversations with risk-averse sponsors prioritizing high-yield, high-purity viral vectors and robust scale-up strategies.

Strategic hiring signals Note executive hires and partnerships (Chief Commercial Officer, Chief of Staff, collaboration with Wistar Institute) as indicators of growth, capability expansion, and potential cross-sell opportunities across research, development, and commercial teams.